BIO-TECHNE (TECH) Getting Somewhat Positive News Coverage, Study Finds

Press coverage about BIO-TECHNE (NASDAQ:TECH) has been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BIO-TECHNE earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.1448847377356 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

BIO-TECHNE (NASDAQ TECH) traded up $0.01 during mid-day trading on Monday, hitting $136.39. 151,313 shares of the stock traded hands, compared to its average volume of 171,460. The company has a market capitalization of $5,109.09, a P/E ratio of 70.67, a P/E/G ratio of 3.40 and a beta of 0.75. BIO-TECHNE has a 12-month low of $95.68 and a 12-month high of $137.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.87 and a quick ratio of 2.25.

BIO-TECHNE (NASDAQ:TECH) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported $0.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.08. The firm had revenue of $144.61 million during the quarter, compared to the consensus estimate of $142.37 million. BIO-TECHNE had a net margin of 12.54% and a return on equity of 14.11%. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.84 earnings per share. sell-side analysts expect that BIO-TECHNE will post 3.76 earnings per share for the current year.

Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a research note on Wednesday, December 27th. Leerink Swann reaffirmed a “buy” rating on shares of BIO-TECHNE in a research note on Tuesday, December 5th. BidaskClub downgraded shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. Deutsche Bank set a $145.00 price target on shares of BIO-TECHNE and gave the company a “buy” rating in a research note on Tuesday, October 31st. Finally, Citigroup reaffirmed a “buy” rating and set a $115.00 price target (down previously from $125.00) on shares of BIO-TECHNE in a research note on Tuesday, October 24th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. BIO-TECHNE has an average rating of “Hold” and a consensus price target of $135.00.

In other news, Director Robert V. Baumgartner sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $130.18, for a total transaction of $650,900.00. Following the completion of the transaction, the director now owns 12,712 shares of the company’s stock, valued at $1,654,848.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.40% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “BIO-TECHNE (TECH) Getting Somewhat Positive News Coverage, Study Finds” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at


Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Insider Buying and Selling by Quarter for BIO-TECHNE (NASDAQ:TECH)

What are top analysts saying about BIO-TECHNE? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BIO-TECHNE and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit